Basic Information
Pixuvri
Regulatory Information
EMEA/H/C/002055
May 10, 2012
February 16, 2012
23
December 7, 2021
Company Information
France
Les Laboratoires Servier 50 rue Carnot F-92284 Suresnes Cedex
LES LABORATOIRES SERVIER
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Pixuvri. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Pixuvri.